BILL ANALYSIS

HR9847

NEUTRAL

Improving CARE for Youth Act

HR9847 (Improving CARE for Youth Act) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR9847 is a procedural Medicaid billing reform with zero authorized funding.

No material revenue impact for any publicly traded company.

Bipartisan sponsorship suggests potential for advancement, but early-stage status and lack of appropriation limit near-term market relevance.

Medicaid managed care stocks ($UNH, $HUM, $CNC, $MOH) face no material change from this bill.

How HR9847 Affects the Market

No market implications. The bill does not affect any company's revenue, costs, or competitive position. Medicaid managed care stocks continue to trade on enrollment trends, capitation rates, and broader healthcare policy (e.g., Medicaid unwinding, ACA subsidies), not on this procedural change.

Bill Details

Metric	Value
Bill Number	HR9847
Market Sentiment	neutral
Event Date	July 22, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR9847, the Improving CARE for Youth Act, is an early-stage bill that would require state Medicaid plans to cover same-day mental health and primary care services. It removes an administrative barrier but does not authorize new funding or expand coverage. The bill is in committee with no appropriation, so near-term market impact is negligible for Medicaid managed care stocks.

Full AI Market Analysis

On July 22, 2026, Rep. Dunn (R-FL) introduced HR9847, the Improving CARE for Youth Act, which was referred to the House Energy and Commerce Committee. The bill amends the Social Security Act to prohibit state Medicaid plans from denying payment for mental health or substance use disorder services and primary care services when furnished on the same day. This is a procedural change to existing Medicaid billing rules, not a new spending program. The money trail is clear: the bill authorizes zero new funding. It is an authorization bill that changes the conditions under which existing Medicaid funds can be used. Actual state-level implementation would require no additional federal appropriation, but states may need to update their managed care contracts and billing systems at administrative cost. The bill has no appropriation language, so no new federal dollars flow to any company. There is no convergence with other signals in the provided data. The bill stands alone as a targeted Medicaid administrative reform. No related procurement, executive action, or companion Senate bill is present. Structural winners and losers: The bill is neutral for Medicaid managed care companies (, $HUM, $CNC, $MOH) because it does not expand the Medicaid population, increase capitation rates, or add new mandatory benefits. It simply removes a billing restriction. Providers (physician groups, FQHCs, rural health clinics) may see modest operational simplification, but no public company is directly and materially affected. The bill's bipartisan cosponsorship (Rep. Carter, D-LA; Rep. Craig, D-MN) suggests it could advance, but as a procedural bill with no funding, its market impact remains near zero. Timeline: The bill is at the earliest legislative stage — referred to committee. It must pass the House, Senate, and be signed by The President to become law. No hearings or markups have occurred. Given the 119th Congress's remaining calendar, passage is uncertain and likely not before 2027.